页 1 从 19 结果
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods deriving from enzyme inhibition.
BACKGROUND
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in which proteins
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods deriving from enzyme inhibition.
BACKGROUND
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in which proteins